Clinical Trials Browser

Malignant Ascites × Immune Checkpoint Inhibitors × Clear all

NCT06433869 2024-05-30

The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites

Phase 2 Recruiting

Malignant Ascites